Targeting the Host for New Therapeutic Perspectives in Hepatitis D.
Fiche publication
Date publication
janvier 2020
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr VERRIER Eloi
Tous les auteurs :
Turon-Lagot V, Saviano A, Schuster C, Baumert TF, Verrier ER
Lien Pubmed
Résumé
Hepatitis D virus (HDV) is a small satellite virus of hepatitis B virus (HBV) requiring HBV infection to complete its life cycle. It has been recently estimated that 13% of chronic HBV infected patients (60 million) are co-infected with HDV. Chronic hepatitis D is the most severe form of viral hepatitis with the highest risk to develop cirrhosis and liver cancer. Current treatment is based on pegylated-interferon-alpha which rarely controls HDV infection and is complicated by serious side effects. The development of novel antiviral strategies based on host targeting agents has shown promising results in phase I/II clinical trials. This review summarizes HDV molecular virology and physiopathology as well as new therapeutic approaches targeting HDV host factors.
Mots clés
Hepatitis D, antiviral strategy, host factors, liver disease
Référence
J Clin Med. 2020 Jan 14;9(1):